Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

CVS Caremark 4th-Quarter Profit Up 2.6% on Higher Sales

share with twitter share with LinkedIn share with facebook
share via e-mail
02/06/2013 | 02:59pm CET

--Debt refinancing costs weigh on bottom line, but sales broadly higher

--PBM, retail sales each rise, helping CVS report better-than-expected results

--Same-store sales growth exceeds monthly data posted by Walgreen, Rite Aid

(Updates with CEO interview comments, additional background and the latest stock quote, beginning in the first paragraph.)

   By John Kell 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as debt refinancing costs weighed on the bottom line, somewhat masking a strong performance for the company's pharmacy-benefits-management business and higher retail sales.

The drugstore retailer and PBM has now reported better-than-expected adjusted earnings for four consecutive quarters. Results in the fourth quarter were led by the PBM business, which saw revenue rise 17% to $18.6 billion, aided by new clients added to the network during the 2012 PBM selling season, higher drug costs and growth in the Medicare Part D program.

On the retail side, the top line jumped 5.1% to $16.3 billion as same-store sales grew 4%, growth that exceeds the monthly sales data posted by rivals Walgreen Co. (>> Walgreen Company) and Rite Aid Corp. (>> Rite Aid Corporation) in late 2012. Prescription volume growth was healthy, aided by client wins after Walgreen's contract dispute last year with fellow PBM Express Scripts Holding Co. (>> Express Scripts Holding Co) and stronger demand for flu-related prescriptions.

But CVS said pharmacy same-store sales were stung by higher usage of low-priced generics, which hurts the top line for drug store chains, though those products have a mixed benefit as they command higher margins.

An active flu season has helped drugstore chains somewhat mitigate the top-line dent caused by higher generic penetration, as consumers seek out vaccinations, order prescriptions and buy over-the-counter cough-and-cold medications. CVS Chief Executive Larry Merlo told Dow Jones Newswires that the company saw a "significant uptick" in flu activity by mid-December and strong demand through most of January.

Mr. Merlo said over the past two weeks, CVS has seen the severity of flu cases moderate. Still, the company has administered about 4.8 million flu shots so far this season, above last year's level.

Overall, CVS reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-related costs and other items, adjusted earnings from continuing operations were $1.14 in the latest quarter. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Gross margin expanded to 20.1% from 19.6%.

For the year, CVS now sees adjusted earnings from continuing operations of $3.86 to $4, a view that was lifted by two cents to reflect the debt refinancing.

CVS will face some lofty comparisons in 2013, due to strong demand for generics, particularly in the first half of the year. And after Walgreen inked a contract agreement with Express Scripts starting in September, the company has had some success winning back some customers it lost to competitors during the months-long spat, resulting in some lost business for CVS.

Shares were up 1.5% to $52.50 in premarket trading.

--Tess Stynes contributed to this article

Write to John Kell at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article
ChangeLast1st jan.
CVS HEALTH -1.51% 60.86 Delayed Quote.-13.90%
EXPRESS SCRIPTS HOLDING CO -0.44% 70.16 Delayed Quote.-5.59%
RITE AID CORPORATION -3.25% 1.49 Delayed Quote.-21.83%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CVS HEALTH
03/23CVS HEALTH : State announces new apprenticeship program, expands modern apprenti..
03/23CVS HEALTH : Disclosed HIV Status of 6,000 Ohioans Putting Their Health, Safety ..
03/22CVS HEALTH : Pharmacy Now Offering New Shingles Vaccine at Locations Nationwide
03/22CVS HEALTH : Receives NCQA Utilization Management Accreditation
03/22Cigna Tells Regulators It Moved Fast On $67 Billion Express Scripts Deal
03/21CVS HEALTH : Launches Two Initiatives in New Hampshire to Combat Opioid Abuse
03/21CVS HEALTH : to Donate $100,000 to The 100 Club of Chicago in Support of the 38t..
03/21CVS HEALTH : State Announces New Apprenticeship Program With CVS Health, Expands..
03/21CVS HEALTH : Hires Former Eli Lilly Executive -- WSJ
03/20CVS HEALTH : Appoints Derica W. Rice as President of CVS Caremark
More news
News from SeekingAlpha
03/23Healthcare Reform, Top Down And Bottom Up 
03/21CVS Health Dividend Stock Analysis 
03/2010 Dividend Growth Stocks For March 2018 
03/2020 Dividend Stocks With Rock-Solid Dividend Growth Prospects 
03/20AAM S&P 500 HIGH DIVIDEND VALUE ETF : Should You Ditch The High Yield Dog For T.. 
Financials ($)
Sales 2018 189 B
EBIT 2018 9 961 M
Net income 2018 5 788 M
Debt 2018 20 750 M
Yield 2018 3,43%
P/E ratio 2018 11,45
P/E ratio 2019 10,20
EV / Sales 2018 0,44x
EV / Sales 2019 0,41x
Capitalization 63 327 M
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 88,2 $
Spread / Average Target 41%
EPS Revisions
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-13.90%63 327